MeiraGTx (NASDAQ:MGTX) CEO Sells 62,000 Shares of Company Stock

MeiraGTx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Alexandria Forbes sold 62,000 shares for $523,900, reducing her direct stake by 4.76% to 1,239,595 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
  • MeiraGTx missed quarterly estimates, reporting a loss of $0.53 per share versus the expected $0.50 loss, and revenue of $4.81 million versus $6.95 million expected.
  • The stock fell $0.28 to $8.46 on Tuesday. Analysts’ consensus rating remains “Moderate Buy,” with an average price target of $24.
  • MarketBeat previews the top five stocks to own by December 1st.

MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $8.45, for a total transaction of $523,900.00. Following the completion of the transaction, the chief executive officer directly owned 1,239,595 shares of the company's stock, valued at $10,474,577.75. This represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

MeiraGTx Price Performance

MGTX stock traded down $0.28 during trading on Tuesday, reaching $8.46. The company's stock had a trading volume of 825,035 shares, compared to its average volume of 647,740. MeiraGTx Holdings PLC has a 1 year low of $6.62 and a 1 year high of $15.35. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $826.80 million, a P/E ratio of 10.58 and a beta of 1.09. The company's fifty day moving average is $10.51 and its 200-day moving average is $10.37.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.03). MeiraGTx had a net margin of 19.46% and a return on equity of 85.23%. The business had revenue of $4.81 million during the quarter, compared to analysts' expectations of $6.95 million. On average, research analysts expect that MeiraGTx Holdings PLC will post 0.20 earnings per share for the current fiscal year.

Trending Headlines about MeiraGTx

These are some of the MGTX headlines that stood out recently:

  • Positive Sentiment: MeiraGTx announced an oral presentation of its AAV-BDNF program for severe early-onset obesity at ObesityWeek 2026. The presentation could increase visibility for the program, though the announcement itself does not report new clinical results. Article: MeiraGTx oral presentation announcement
  • Negative Sentiment: HC Wainwright lowered its earnings estimates across 2026 and 2027. It cut its FY2026 EPS forecast to $0.10 from $0.36 and its FY2027 forecast to a loss of $1.83 per share from a loss of $1.45, also reducing estimates for each quarter from Q4 2026 through Q4 2027. The broader downward revisions may weigh on expectations for profitability. MarketBeat MGTX coverage

Analyst Upgrades and Downgrades

MGTX has been the topic of several recent analyst reports. Zacks Research downgraded MeiraGTx from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 11th. Wall Street Zen downgraded MeiraGTx from a "buy" rating to a "hold" rating in a research note on Saturday. Royal Bank Of Canada increased their price objective on shares of MeiraGTx from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Friday, August 14th. Weiss Ratings lowered shares of MeiraGTx from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday. Finally, The Goldman Sachs Group began coverage on shares of MeiraGTx in a research report on Thursday, September 24th. They set a "neutral" rating and a $16.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $24.00.

Read Our Latest Stock Analysis on MeiraGTx

Institutional Trading of MeiraGTx

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of MeiraGTx by 250.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,147,015 shares of the company's stock valued at $12,617,000 after purchasing an additional 819,599 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in shares of MeiraGTx by 13.3% during the third quarter. Tocqueville Asset Management L.P. now owns 88,000 shares of the company's stock valued at $968,000 after purchasing an additional 10,300 shares in the last quarter. Polymer Capital Management US LLC bought a new stake in shares of MeiraGTx in the third quarter worth about $121,000. Meeder Asset Management Inc. bought a new stake in shares of MeiraGTx in the third quarter worth about $52,000. Finally, Global Retirement Partners LLC bought a new stake in shares of MeiraGTx in the third quarter worth about $34,000. Hedge funds and other institutional investors own 67.48% of the company's stock.

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

Recommended Stories

Insider Buying and Selling by Quarter for MeiraGTx (NASDAQ:MGTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MeiraGTx Right Now?

Before you consider MeiraGTx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.

While MeiraGTx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines